16.11.2013 Views

45 – Healthcare Providers and Services, and Healthcare Technology

45 – Healthcare Providers and Services, and Healthcare Technology

45 – Healthcare Providers and Services, and Healthcare Technology

SHOW MORE
SHOW LESS

Transform your PDFs into Flipbooks and boost your revenue!

Leverage SEO-optimized Flipbooks, powerful backlinks, and multimedia content to professionally showcase your products and significantly increase your reach.

This table shows a list of topics identified as relevant by different stakeholder groups. They can be considered as stakeholders’ suggestions or requests<br />

for topics to be monitored or disclosed by organizations.<br />

Additional information about the project can be found at https://www.globalreporting.org/reporting/sector-guidance/Topics-<br />

Research/Pages/default.aspx<br />

<strong>45</strong> <strong>–</strong> <strong>Healthcare</strong> <strong>Providers</strong> <strong>and</strong> <strong>Services</strong>, <strong>and</strong> <strong>Healthcare</strong> <strong>Technology</strong><br />

21 Topics<br />

<strong>Providers</strong> of patient health care services. Includes dialysis centers, lab testing services, <strong>and</strong> pharmacy management services. Also includes<br />

companies providing business support services to health care providers, such as clerical support services, collection agency services, staffing<br />

services <strong>and</strong> outsourced sales & marketing services. Owners <strong>and</strong> operators of health care facilities, including hospitals, nursing homes,<br />

rehabilitation centers <strong>and</strong> animal hospitals. Owners <strong>and</strong> operators of Health Maintenance Organizations (HMOs) <strong>and</strong> other managed plans.<br />

Companies providing information technology services primarily to health care providers. Includes companies providing application, systems<br />

<strong>and</strong>/or data processing software, internet-based tools, <strong>and</strong> IT consulting services to doctors, hospitals or businesses operating primarily in the<br />

health care sector. Distributors <strong>and</strong> wholesalers of health care products not included elsewhere.<br />

Sustainability<br />

Category<br />

Environmental<br />

Topic<br />

Toxic chemicals<br />

<strong>and</strong> materials<br />

Topic<br />

Specification<br />

(if available)<br />

Hazardous<br />

chemical <strong>and</strong><br />

toxin use<br />

Explanation Reference(s) 1 Constituency<br />

Health care facilities around the world are reducing their<br />

use of hazardous chemicals <strong>and</strong> products. For example:<br />

More than 6,000 health care facilities in the U.S. are<br />

eliminating mercury-containing medical devices in favor<br />

of safer non-mercury alternatives<br />

Hospitals from Stockholm, to Prague, <strong>and</strong> throughout the<br />

U.S. are phasing out phthalate-containing PVC medical<br />

devices <strong>and</strong> switching to safer plastics<br />

232, 496 Business<br />

Sustainability Topics for Sectors: What do stakeholders want to know?<br />

HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />

May 2013<br />

Page 1 of 26


Sustainability<br />

Category<br />

Topic<br />

Topic<br />

Specification<br />

(if available)<br />

Explanation Reference(s) 1 Constituency<br />

Many hospitals are reducing pesticides by using<br />

integrated pest management techniques<br />

Many hospitals are choosing safer, less toxic building<br />

materials for new construction <strong>and</strong> renovation projects.<br />

Green chemistry is the design of products <strong>and</strong> processes<br />

that reduce or eliminate the use <strong>and</strong> generation of<br />

hazardous substances. Green chemistry seeks to reduce<br />

<strong>and</strong> prevent pollution at its source.<br />

High-priority chemicals <strong>and</strong> materials include:<br />

Mercury<br />

PVC (vinyl plastic) <strong>and</strong> phthalates<br />

Brominated flame retardants<br />

Glutaraldehyde <strong>and</strong> ethylene oxide<br />

Pesticides<br />

Volatile organic compounds in building materials<br />

Hazardous ingredients in cleaning products.<br />

Green chemistry is the design of products <strong>and</strong> processes<br />

that reduce or eliminate the use <strong>and</strong> generation of<br />

hazardous substances. Green chemistry seeks to reduce<br />

<strong>and</strong> prevent pollution at its source.<br />

The ubiquitous exposure to toxic chemicals in everyday<br />

life has increasingly become a health concern.<br />

Unfortunately, many products used in health care<br />

contribute to hazardous exposures — including cleaners<br />

<strong>and</strong> disinfectants, phthalates in medical devices, flame<br />

retardants in furniture, formaldehyde in furniture <strong>and</strong><br />

solvents in labs.<br />

Emerging scientific research is raising the level of<br />

Sustainability Topics for Sectors: What do stakeholders want to know?<br />

HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />

May 2013<br />

Page 2 of 26


Sustainability<br />

Category<br />

Topic<br />

Topic<br />

Specification<br />

(if available)<br />

Explanation Reference(s) 1 Constituency<br />

concern about the health impacts of chronic chemical<br />

exposures. We now know that: Even small doses of<br />

chemicals can cause disease — interfering with sexual<br />

development, disrupting hormones <strong>and</strong> causing cancer at<br />

very low levels. Children <strong>and</strong> developing babies are most<br />

vulnerable. Hundreds of synthetic chemicals are found in<br />

human breast milk <strong>and</strong> in the cord blood of babies in the<br />

womb. Chemicals can act like drugs in our body,<br />

disrupting systems at low levels of exposure, <strong>and</strong><br />

potentially causing harm in combination.<br />

Chemical Related Diseases: As chemical use has grown in<br />

industrialized societies, so have chemical-related<br />

diseases, including cancer, asthma, birth defects,<br />

developmental disabilities, autism, endometriosis <strong>and</strong><br />

infertility. Mounting scientific evidence links the<br />

incidence of these diseases in part to environmental<br />

toxicants. Health care institutions have a particular<br />

ethical responsibility to use products containing<br />

chemicals that pose less risk to human health — <strong>and</strong> due<br />

to their massive buying power, the health care system<br />

can play a key role in shifting the economy toward green<br />

chemistry.<br />

A growing number of hospitals are taking a "better safe<br />

than sorry" approach to chemicals — eliminating<br />

suspected hazards <strong>and</strong> switching to safer alternatives.<br />

Benefits of this approach to the bottom line can include<br />

reduced disposal costs, reduced liability <strong>and</strong> improved<br />

health for employees.<br />

Sustainability Topics for Sectors: What do stakeholders want to know?<br />

HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />

May 2013<br />

Page 3 of 26


Sustainability<br />

Category<br />

Topic<br />

Topic<br />

Specification<br />

(if available)<br />

Explanation Reference(s) 1 Constituency<br />

Toxins with an especially heavy impact in the health care<br />

sector may be found in:<br />

489 Business<br />

Cleaners <strong>and</strong> disinfectants<br />

Dioxin-containing byproducts<br />

Electronic equipment<br />

Flame retardants<br />

Fragrance chemicals<br />

Mercury-containing medical devices <strong>and</strong> wastes<br />

Pesticides<br />

Phthalates <strong>and</strong> DEHP<br />

PVC<br />

Health care institutions, like institutions outside the<br />

health care sector, regularly use a surprising number of<br />

highly toxic materials. These toxins affect patients,<br />

hospital staff, <strong>and</strong> hospital visitors.<br />

Plastics use <strong>and</strong><br />

management<br />

Many of these toxins are defined <strong>and</strong> regulated by<br />

federal, state <strong>and</strong> local laws. Others are used daily but<br />

hardly regulated at all. They include carcinogens,<br />

materials that damage the skin <strong>and</strong> organs, <strong>and</strong> materials<br />

that corrode, irritate, or release other toxins in the<br />

course of normal use, storage, transportation or disposal.<br />

Plastic, a valuable material, can generate significant<br />

positive, or negative, impacts on economy, environment<br />

<strong>and</strong> society. Plastic should be treated as a resource <strong>and</strong><br />

managed judiciously.<br />

A disclosure on management approach for plastics,<br />

353, 367 Civil Society<br />

Organization<br />

Sustainability Topics for Sectors: What do stakeholders want to know?<br />

HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />

May 2013<br />

Page 4 of 26


Sustainability<br />

Category<br />

Topic<br />

Topic<br />

Specification<br />

(if available)<br />

Explanation Reference(s) 1 Constituency<br />

including governance, strategy, risks, opportunities,<br />

considering: opportunities for product redesign,<br />

increasing recycled content, implementing reclaim<br />

<strong>and</strong>/or reuse which could attract economies, br<strong>and</strong><br />

loyalty, investment, employee goodwill, <strong>and</strong>; risks to the<br />

business, stakeholder health, environment <strong>and</strong> society<br />

(including reputational/social license to operate,<br />

regulatory, investor, insurer, <strong>and</strong> liability risks) for<br />

plastics that are directly harmful to stakeholders, or<br />

indirectly through plastics being wasted/littered.<br />

Performance indicators regarding the types <strong>and</strong> volumes<br />

of plastics being used, collected <strong>and</strong>/or distributed<br />

downstream; the portion that is made of post-consumerrecycled,<br />

bio-based, biodegradable, compostable, <strong>and</strong>/or<br />

oxobiodegradable material; the ratio of expected lifespan<br />

of plastic products/packaging in contrast to the<br />

duration of their intended use; these volumes broken<br />

down by end of life disposition.<br />

Most of this disclosure can be captured through the<br />

existing GRI framework (e.g. GRI G3 EC9, EN1, EN2,<br />

EN22), but commentary is needed to ensure disclosers<br />

appreciate the materiality of plastic; other questions can<br />

be added to the framework. Refer to the Plastic<br />

Disclosure Project ( www.plasticdisclosure.org ) for more<br />

details on the suggested questions. PDP will align its<br />

questions to GRI G4 to assist disclosers.<br />

Plastic are in high use in these "activity groups", <strong>and</strong> can<br />

have significant positive, or negative, impacts on the<br />

economy, environment <strong>and</strong> society: Economics: There<br />

Sustainability Topics for Sectors: What do stakeholders want to know?<br />

HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />

May 2013<br />

Page 5 of 26


Sustainability<br />

Category<br />

Topic<br />

Topic<br />

Specification<br />

(if available)<br />

Explanation Reference(s) 1 Constituency<br />

are significant cost savings available to organisations that<br />

treat plastic as a resource (e.g. through redesign, use of<br />

recycled content, reclaiming, etc.) <strong>and</strong> risks of increased<br />

direct costs (regulation, liability, cost of capital,<br />

insurance) to organisations that do not lead in this area<br />

as well as indirect economic costs to impacted industries<br />

(e.g. food production, tourism). Environment: Plastics<br />

that are wasted or littered become extremely harmful to<br />

the environment, which will have a material effect on<br />

biodiversity <strong>and</strong> the global food chain, both nearby <strong>and</strong><br />

far outside the local area of operations. Society: Some<br />

plastics are harmful to stakeholders during manufacture,<br />

use <strong>and</strong>/or disposal (e.g. due to phthalates, BPA), impact<br />

the wellbeing of society (e.g. effect of litter on<br />

community spirit <strong>and</strong> their interest in sustainability).<br />

While a valuable invention, which benefits society in<br />

many ways, the negative impacts associated with<br />

society's growing use of plastic are not fully recognised.<br />

Roughly 85% of plastic used in products <strong>and</strong> packaging is<br />

not recycled, <strong>and</strong> most plastic produced in the last 60<br />

years still remains in the environment today. Discarded<br />

plastics persist in the environment for dozens or<br />

hundreds of years, accumulating across the globe, often<br />

out of sight of the producers <strong>and</strong> users. The direct<br />

physical impacts of plastic are significant to the<br />

organisation in increased costs or missed opportunities,<br />

<strong>and</strong> related economies (e.g. over $1.2bn in annual<br />

damages to ocean-related industries in Asia-Pacific), the<br />

environment through harming habitats <strong>and</strong> species, <strong>and</strong><br />

Sustainability Topics for Sectors: What do stakeholders want to know?<br />

HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />

May 2013<br />

Page 6 of 26


Sustainability<br />

Category<br />

Topic<br />

<strong>Healthcare</strong><br />

waste<br />

management<br />

Topic<br />

Specification<br />

(if available)<br />

<strong>Healthcare</strong>,<br />

medical<br />

research<br />

facilities <strong>and</strong><br />

laboratories<br />

Explanation Reference(s) 1 Constituency<br />

to stakeholders health when exposed to the chemical<br />

ingredients; <strong>and</strong> are magnified if fragmentation of the<br />

plastic occurs, making it available for ingestion to<br />

additional species, who adsorb the chemical ingredients<br />

<strong>and</strong>/or the toxins carried on the plastic. These negative<br />

impacts could be avoided <strong>and</strong> turned into positive<br />

impacts, if plastic was treated as a resource to be<br />

managed judiciously (e.g. the US economy lost $8.3bn<br />

worth of plastic packaging in 2010) - "It is not good<br />

business practice to throw away valuable resources".<br />

Medical waste is all waste materials generated at health<br />

care facilities, such as hospitals, clinics, physician's<br />

offices, dental practices, blood banks, <strong>and</strong> veterinary<br />

hospitals/clinics, as well as medical research facilities <strong>and</strong><br />

laboratories.<br />

102, 242 Business<br />

The Medical Waste tracking Act of 1988 defines medical<br />

waste as "any solid waste that is generated in the<br />

diagnosis, treatment, or immunization of human beings<br />

or animals, in research pertaining thereto, or in the<br />

production or testing of biologicals." This definition<br />

includes, but is not limited to:<br />

blood-soaked b<strong>and</strong>ages<br />

culture dishes <strong>and</strong> other glassware<br />

discarded surgical gloves<br />

discarded surgical instruments<br />

discarded needles used to give shots or draw blood<br />

(e.g., medical sharps)<br />

cultures, stocks, swabs used to inoculate cultures<br />

Sustainability Topics for Sectors: What do stakeholders want to know?<br />

HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />

May 2013<br />

Page 7 of 26


Sustainability<br />

Category<br />

Topic<br />

Topic<br />

Specification<br />

(if available)<br />

Explanation Reference(s) 1 Constituency<br />

removed body organs (e.g., tonsils, appendices, limbs)<br />

discarded lancets<br />

Hospitals generate millions of tons of waste each year. In<br />

the past, many hospitals simply dumped all waste<br />

streams together, from reception-area trash to<br />

operating-room waste, <strong>and</strong> burned them in incinerators<br />

— <strong>and</strong> this is still common practice in many developing<br />

countries.<br />

Infectious waste<br />

Yet medical waste incineration is a leading source of<br />

dioxin, mercury, lead <strong>and</strong> other dangerous pollutants<br />

that threaten human health <strong>and</strong> the environment.<br />

Despite these dangers, many governments, public health<br />

agencies, international organizations <strong>and</strong> transnational<br />

corporations continue to promote incineration<br />

technologies as waste management "solutions."<br />

Infectious waste is waste that is suspected to contain<br />

pathogens (disease-causing bacteria, viruses, parasites,<br />

or fungi) in sufficient concentration or quantity to cause<br />

disease in susceptible hosts. The subcategories of<br />

infectious waste are (a) waste contaminated with blood<br />

or other body fluids; (b) microbiological cultures <strong>and</strong><br />

stocks of infectious agents from laboratory work; <strong>and</strong> (c)<br />

waste from infected patients in isolation wards. Waste<br />

contaminated with blood or other body fluids include:<br />

free-flowing blood, blood components, <strong>and</strong> other body<br />

fluids (semen, vaginal secretions, cerebrospinal fluid,<br />

synovial fluid, pleural fluid, pericardial fluid, peritoneal<br />

527 Civil Society<br />

Organization<br />

Sustainability Topics for Sectors: What do stakeholders want to know?<br />

HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />

May 2013<br />

Page 8 of 26


Sustainability<br />

Category<br />

Topic<br />

Topic<br />

Specification<br />

(if available)<br />

Explanation Reference(s) 1 Constituency<br />

fluid, amniotic fluid, saliva <strong>and</strong> other body fluids visibly<br />

contaminated with blood); dressings, b<strong>and</strong>ages, swabs,<br />

gloves, masks, gowns, drapes, <strong>and</strong> other material<br />

contaminated with blood or other body fluids; <strong>and</strong> waste<br />

that has been in contact with the blood of patients<br />

undergoing hemodialysis (e.g. dialysis equipment such as<br />

tubing <strong>and</strong> filters, disposable towels, gowns, aprons,<br />

gloves, <strong>and</strong> laboratory coats).<br />

With regards to infectious healthcare waste, there are<br />

four approaches to healthcare waste treatment. A<br />

decentralized approach is one where the technology is<br />

installed on-site at the healthcare facility. By treating the<br />

waste as close as possible to the point of generation, this<br />

approach has the advantage of eliminating the transport<br />

of hazardous healthcare waste.<br />

Another approach is centralized treatment at an off-site<br />

facility designed to h<strong>and</strong>le the waste from hospitals,<br />

clinics, medical laboratories, doctors‘ offices, <strong>and</strong> other<br />

health facilities in a large urban center, province, or<br />

region. This approach requires the transport of infectious<br />

waste from many sources to the central treatment<br />

facility <strong>and</strong> is only possible if there is a good<br />

infrastructure for collection, transport <strong>and</strong> temporary<br />

storage. Its major benefit is cost reduction as it takes<br />

advantage of the economies of scale.<br />

A third approach is cluster treatment wherein a hospital<br />

serves as a hub for treating waste from surrounding<br />

nearby hospitals, clinics, <strong>and</strong> other facilities. Cluster<br />

treatment is an option for small municipalities, parts of a<br />

Sustainability Topics for Sectors: What do stakeholders want to know?<br />

HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />

May 2013<br />

Page 9 of 26


Sustainability<br />

Category<br />

Topic<br />

Topic<br />

Specification<br />

(if available)<br />

Explanation Reference(s) 1 Constituency<br />

province, or districts that may be too far from a central<br />

treatment facility but have an adequate infrastructure<br />

for collection <strong>and</strong> transport of infectious waste within<br />

their area.<br />

A fourth approach is mobile treatment. In this approach,<br />

the treatment technology is mounted on a mobile<br />

platform, such as a specially designed mobile container<br />

or a flatbed truck, <strong>and</strong> is brought to hospitals <strong>and</strong> other<br />

health facilities within a service territory. The mobile<br />

treatment system treats <strong>and</strong> converts infectious waste<br />

into regular waste as the mobile unit is parked on the<br />

hospital grounds. After treatment, the system is driven<br />

to the next healthcare facility.<br />

Pharmaceutical<br />

products <strong>and</strong><br />

items for<br />

h<strong>and</strong>ling them<br />

Improper treatment <strong>and</strong> disposal of healthcare waste<br />

pose serious hazards of disease transmission due to<br />

exposures to infectious agents among waste pickers,<br />

waste workers, health workers, patients, <strong>and</strong> the<br />

community in general.<br />

For a healthcare facility, several practical options exist<br />

for small quantities of pharmaceutical waste: return of<br />

expired pharmaceuticals to the donor or manufacturer;<br />

encapsulation <strong>and</strong> burial in a sanitary l<strong>and</strong>fill; chemical<br />

decomposition in accordance with the manufacturer‘s<br />

recommendations if chemical expertise <strong>and</strong> materials are<br />

available; <strong>and</strong> dilution in large amounts of water <strong>and</strong><br />

sewer discharge into a sewer for moderate quantities of<br />

relatively mild liquid or semi-liquid pharmaceuticals, such<br />

as solutions containing vitamins, cough syrups,<br />

intravenous solutions <strong>and</strong> eye drops.<br />

527 Civil Society<br />

Organization<br />

Sustainability Topics for Sectors: What do stakeholders want to know?<br />

HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />

May 2013<br />

Page 10 of 26


Sustainability<br />

Category<br />

Topic<br />

Topic<br />

Specification<br />

(if available)<br />

Explanation Reference(s) 1 Constituency<br />

Pharmaceutical waste includes expired, unused, spilled,<br />

<strong>and</strong> contaminated pharmaceutical products, drugs,<br />

vaccines, <strong>and</strong> sera that are no longer needed. The<br />

classification also includes discarded items used in the<br />

h<strong>and</strong>ling of pharmaceuticals, such as bottles, boxes,<br />

gloves, masks, vials, <strong>and</strong> tubing contaminated with<br />

pharmaceutical residues.<br />

Improper treatment <strong>and</strong> disposal of pharmaceutical<br />

healthcare waste pose risks, because for example waste<br />

scavengers might collect the expired, unused, spilled,<br />

<strong>and</strong> contaminated pharmaceutical products, drugs,<br />

vaccines, <strong>and</strong> sera that are no longer needed, <strong>and</strong> take or<br />

sell them.<br />

The huge quantities of medicines ending up in waste or<br />

in aquatic systems are a major environmental health<br />

issue. The increasing documentation of low-dose health<br />

effects makes pharmaceuticals a priority area from an<br />

environmental health perspective. Hundreds of different<br />

active pharmaceutical compounds are being discovered<br />

in waterways all over the world. Concern is increasing<br />

about the harm these might be doing to human health<br />

<strong>and</strong> the environment.<br />

44, 240 Business<br />

Although levels are usually too low to result in acute<br />

effects such as organ damage, there are two cases where<br />

drugs have had drastic effects: where the antiinflammatory<br />

diclofenac has virtually wiped out the<br />

vulture population of Asia, while man-made estradiol has<br />

Sustainability Topics for Sectors: What do stakeholders want to know?<br />

HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />

May 2013<br />

Page 11 of 26


Sustainability<br />

Category<br />

Topic<br />

Topic<br />

Specification<br />

(if available)<br />

Explanation Reference(s) 1 Constituency<br />

caused fish to start changing sex.<br />

Although the levels of other drugs don't cause acute<br />

reactions, there is little or no information about the nonacute<br />

effects which low doses might have on wildlife <strong>and</strong><br />

humans.<br />

There are suggestions in research that contaminated<br />

water affects fish in subtle ways, such as changing<br />

breeding behaviour. This may cause declines in<br />

populations, or even be an indicator of other problems.<br />

Ordinary risk assessment is of limited value in<br />

determining the environmental hazard posed by low<br />

levels of pharmaceutical compounds, as it only looks at<br />

acute effects, struggles to assess the potential effects of<br />

mixtures of compounds, <strong>and</strong> has no way to anticipate<br />

freak reactions.<br />

What we do know is that pharmaceutical compounds are<br />

biologically active <strong>and</strong> they are detectable in our<br />

waterways. We can be sure that it would be better if<br />

they were not there. Therefore, we need to take steps to<br />

deal with the problem.<br />

While patients should be allowed access to the best<br />

available pharmaceutical treatment, other things being<br />

equal, we should consider the medicine's PBT<br />

(persistence, bioaccumulation <strong>and</strong> toxicity) when<br />

developing, manufacturing, prescribing, purchasing,<br />

Sustainability Topics for Sectors: What do stakeholders want to know?<br />

HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />

May 2013<br />

Page 12 of 26


Sustainability<br />

Category<br />

Topic<br />

Topic<br />

Specification<br />

(if available)<br />

<strong>Technology</strong> for<br />

waste<br />

sterilization<br />

<strong>and</strong>/or<br />

destruction<br />

Explanation Reference(s) 1 Constituency<br />

donating <strong>and</strong> disposing of medicines. Our collective aim<br />

should be to protect people <strong>and</strong> the environment from<br />

contamination of hazardous chemicals that wouldn't<br />

otherwise be there.<br />

A wide range of alternative technologies are now<br />

commercially available. Steam sterilization in autoclaves<br />

is the most common alternative treatment method.<br />

Since autoclaves have been used in the treatment of<br />

infectious waste for many decades, their operation is<br />

well established. Several types of steam sterilizers or<br />

autoclaves are available: gravity-fed, pre-vacuum <strong>and</strong><br />

pulse or multivacuum cycle autoclaves. Unlike<br />

incinerators, autoclaves heat the waste to temperatures<br />

high enough to disinfect but not hot enough to burn <strong>and</strong><br />

create air pollutants such as dioxins <strong>and</strong> furans. A posttreatment<br />

shredder or grinder could be used if the waste<br />

is to be rendered unrecognizable <strong>and</strong> if reduction of<br />

waste volume is desired. Microwave treatment is<br />

another type of alternative technology. For years, the<br />

most common microwave device has been a medium- to<br />

large-scale, semi-continuous system using an internal<br />

shredder, rotating internal screw, <strong>and</strong> industrial<br />

magnetrons to generate microwave energy. There are<br />

also commercial dry heat treatment technologies. Moist<br />

heat has been shown to be more effective than dry heat<br />

in achieving disinfection, so dry heat systems generally<br />

require longer exposure times <strong>and</strong> higher temperatures<br />

to meet minimum disinfection levels.<br />

123, 241 Business<br />

Medical waste incineration is a leading source of dioxin<br />

Sustainability Topics for Sectors: What do stakeholders want to know?<br />

HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />

May 2013<br />

Page 13 of 26


Sustainability<br />

Category<br />

Topic<br />

Topic<br />

Specification<br />

(if available)<br />

Explanation Reference(s) 1 Constituency<br />

pollution, one of the most potent carcinogens known to<br />

science. Fortunately, there are viable alternatives to<br />

incineration that are safer, cleaner, do not produce<br />

dioxin, <strong>and</strong> are just as effective at disinfecting medical<br />

waste. These technologies can be used on all types of<br />

medical waste, including pathological <strong>and</strong> chemotherapy<br />

waste.<br />

Given that alternatives to incineration are available, a<br />

complete phase-out of medical waste incineration is<br />

possible <strong>and</strong> appropriate. This will require changes in<br />

state laws, persuasion of hospital systems that non-burn<br />

approaches are both effective <strong>and</strong> environmentally<br />

preferable, public education, <strong>and</strong> better segregation <strong>and</strong><br />

reduction of waste by hospitals. Pathological <strong>and</strong><br />

chemotherapeutic wastes can be treated using alkaline<br />

hydrolysis technology which combines steam sterilization<br />

with tissue digestion using sodium or potassium<br />

hydroxide.<br />

Investment <strong>and</strong> commitment in the management of<br />

health care waste (a by-product of healthcare that<br />

includes sharps, non-sharps, blood, body parts,<br />

chemicals, pharmaceuticals, medical devices <strong>and</strong><br />

radioactive materials).<br />

4<strong>45</strong> Mediating<br />

Institution<br />

Poor management of health care waste potentially<br />

exposes health care workers, waste h<strong>and</strong>lers, patients<br />

<strong>and</strong> the community at large to infection, toxic effects <strong>and</strong><br />

injuries, <strong>and</strong> risks polluting the environment.<br />

<strong>Healthcare</strong> waste is a by-product of healthcare that<br />

includes sharps, non-sharps, blood, body parts,<br />

593 Mediating<br />

Institution<br />

Sustainability Topics for Sectors: What do stakeholders want to know?<br />

HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />

May 2013<br />

Page 14 of 26


Sustainability<br />

Category<br />

Topic<br />

Topic<br />

Specification<br />

(if available)<br />

Explanation Reference(s) 1 Constituency<br />

chemicals, pharmaceuticals, medical devices <strong>and</strong><br />

radioactive materials<br />

Social Migrant workers Recruitment<br />

<strong>and</strong><br />

employment<br />

Poor management of healthcare waste exposes<br />

healthcare workers, waste h<strong>and</strong>lers <strong>and</strong> the community<br />

to infections, toxic effects <strong>and</strong> injuries<br />

Recruitment <strong>and</strong> employment of migrant workers<br />

Number of migrant workers employed<br />

Countries of origin<br />

Gender of workers<br />

Positions within company<br />

Length of contracts<br />

Recruitment channels<br />

Any fees for recruitment<br />

Passport retention<br />

Migrant workers both internal <strong>and</strong> external are a<br />

significant <strong>and</strong> growing feature of all company activities.<br />

There are over 200 million migrants in the world. They<br />

are found within nearly all business sectors <strong>and</strong> across all<br />

regions. Many migrant workers, particularly those<br />

working in unskilled jobs are subject to discrimination<br />

<strong>and</strong> are vulnerable to exploitation <strong>and</strong> abuse.<br />

For many migrants exploitation begins during<br />

recruitment. Exorbitant fees <strong>and</strong> other charges, often at<br />

usurious rates of interest can leave many migrant<br />

workers effectively bonded labour whatever the<br />

subsequent conditions of employment.<br />

253 Mediating<br />

Institution<br />

Sustainability Topics for Sectors: What do stakeholders want to know?<br />

HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />

May 2013<br />

Page 15 of 26


Sustainability<br />

Category<br />

Topic<br />

Privacy of<br />

medical records<br />

<strong>and</strong> genetic data<br />

Topic<br />

Specification<br />

(if available)<br />

Explanation Reference(s) 1 Constituency<br />

Company due diligence <strong>and</strong> reporting should therefore<br />

extend into the supply chain for labour.<br />

The storage <strong>and</strong> uses made of health records <strong>and</strong> the<br />

results of genetic tests raise questions in relation to the<br />

right to privacy.<br />

66 Mediating<br />

Institution<br />

Access to quality<br />

medical<br />

treatments<br />

Care quality<br />

Racial <strong>and</strong><br />

ethnic<br />

disparities<br />

Staff training,<br />

staffing ratios<br />

per patient <strong>and</strong><br />

turnover rates<br />

This case raises questions about the right to privacy of<br />

the people from whom the samples were taken. There<br />

has, for example, been concern that samples of this kind<br />

could be used in paternity suits or to assess health<br />

insurance risks. AT the other h<strong>and</strong>, Retention of the<br />

samples has significant potential public health benefits,<br />

such as retrospective diagnosis from the stored blood<br />

spot, even after the individual is deceased, to help<br />

provide counselling to the family. Approved research can<br />

provide information that is of public health interest or<br />

information that can provide a better underst<strong>and</strong>ing on<br />

how diseases develop, identifying potential opportunities<br />

for intervention.<br />

Measures taken to eliminate racial <strong>and</strong> ethnic disparities<br />

in providing treatments.<br />

Minorities can be treated in a disadvantageous way in<br />

health care as in all other areas in life<br />

Adequate <strong>and</strong> properly trained staff are critical to<br />

healthcare, oil <strong>and</strong> gas <strong>and</strong> financial services.<br />

<strong>Healthcare</strong> providers, including hospitals, nursing homes<br />

<strong>and</strong> home health care need to report on staffing ratios<br />

per patient <strong>and</strong> their turn-over rates. This information<br />

494 Business<br />

2<strong>45</strong>, 362 Labor<br />

Sustainability Topics for Sectors: What do stakeholders want to know?<br />

HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />

May 2013<br />

Page 16 of 26


Sustainability<br />

Category<br />

Topic<br />

Topic<br />

Specification<br />

(if available)<br />

Explanation Reference(s) 1 Constituency<br />

directly indicates the quality of care provided.<br />

with the Volker rule (US Dodd-Frank) are critical to<br />

solvency.<br />

Clinical trials<br />

Disease spread<br />

control<br />

Food quality<br />

Consent<br />

processes<br />

Health care<br />

facilities<br />

Catering<br />

services<br />

Extensive academic research <strong>and</strong> judicial decisions as<br />

well as federal <strong>and</strong> state legislation make these material<br />

indicators for sustainability. See, for example, "Hospital<br />

Nurse Staffing <strong>and</strong> Patient Mortality, Nurse Burnout, <strong>and</strong><br />

Job Dissatisfaction," JAMA. 2002; 288(16):1987-1993.<br />

doi:10.1001/jama.288.16.1987;<br />

Article 7 states that “no one shall be subjected without<br />

his free consent to medical <strong>and</strong> scientific<br />

experimentation”. Several companies <strong>and</strong> research<br />

bodies have faced media <strong>and</strong> legal scrutiny over consent<br />

processes used in clinical trials, irrespective of their<br />

medical success or failure<br />

Acute respiratory diseases during health care may<br />

constitute a public health emergency of international<br />

concern as defined in the International Health<br />

Regulations<br />

<strong>Healthcare</strong> providers should take into account the<br />

following topics when designing the menu for their<br />

patients:<br />

* Antibiotics<br />

*Chemicals in the food system<br />

Genetically engineered foods<br />

*greening serviceware<br />

*hospital food environments<br />

*climate change (by buying local products for example)<br />

66 Mediating<br />

Institution<br />

583, 586 Civil Society<br />

Organization<br />

357 Business<br />

Sustainability Topics for Sectors: What do stakeholders want to know?<br />

HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />

May 2013<br />

Page 17 of 26


Sustainability<br />

Category<br />

Topic<br />

Health service<br />

effectiveness<br />

Topic<br />

Specification<br />

(if available)<br />

Cost<br />

effectiveness of<br />

key health<br />

interventions<br />

Explanation Reference(s) 1 Constituency<br />

Health care facilities across the continent are<br />

recognizing that the food system — how our food is<br />

produced <strong>and</strong> distributed — is misaligned with dietary<br />

guidelines, <strong>and</strong> is largely reliant on methods of<br />

production <strong>and</strong> distribution that harm public <strong>and</strong><br />

environmental health.<br />

The food system is inherently a deeply complex <strong>and</strong><br />

interwoven concept that must be considered from an<br />

integrative, ecological perspective in order to develop<br />

solutions that nourish our health <strong>and</strong> that of the planet.<br />

Healthy Food in Health Care has selected a broadreaching<br />

scope of topics of concern that form the basis<br />

for our work. These issues, like antibiotic resistance, for<br />

example, cut to the core of a hospital’s operations.<br />

Others, like climate change <strong>and</strong> genetically engineered<br />

foods, are matters of serious public health concern that<br />

we believe the health care community has a capacity <strong>and</strong><br />

power to influence.<br />

Some systems devote resources to expensive<br />

interventions with small effects on population health,<br />

while at the same time low cost interventions with<br />

potentially greater benefits are not fully implemented.<br />

The impact of interventions on population health is vital.<br />

But it is also important to determine the role of different<br />

interventions in contributing to other socially desirable<br />

goals, such as reducing health inequalities, <strong>and</strong> being<br />

responsive to the legitimate expectations of the<br />

population<br />

584 Mediating<br />

Institution<br />

The impact of interventions on population health is vital.<br />

Sustainability Topics for Sectors: What do stakeholders want to know?<br />

HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />

May 2013<br />

Page 18 of 26


Sustainability<br />

Category<br />

Topic<br />

Medicines<br />

management<br />

Topic<br />

Specification<br />

(if available)<br />

Patient safety<br />

<strong>and</strong><br />

environmental<br />

impacts<br />

Explanation Reference(s) 1 Constituency<br />

But it is also important to determine the role of different<br />

interventions in contributing to other socially desirable<br />

goals, such as reducing health inequalities, <strong>and</strong> being<br />

responsive to the legitimate expectations of the<br />

population<br />

Rational use of medicines requires that "patients receive<br />

medications appropriate to their clinical needs, in doses<br />

that meet their own individual requirements, for an<br />

adequate period of time, <strong>and</strong> at the lowest cost to them<br />

<strong>and</strong> their community<br />

590 Mediating<br />

Institution<br />

Corruption<br />

Access to <strong>and</strong><br />

quality of<br />

treatments<br />

Irrational use of medicines is a major problem<br />

worldwide. WHO estimates that more than half of all<br />

medicines are prescribed, dispensed or sold<br />

inappropriately, <strong>and</strong> that half of all patients fail to take<br />

them correctly. The overuse, underuse or misuse of<br />

medicines results in wastage of scarce resources <strong>and</strong><br />

widespread health hazards<br />

Measures taken to avoid corruption in the following<br />

processes: provision of services by medical personnel,<br />

human resources management, drug selection <strong>and</strong> use,<br />

procurement of drugs <strong>and</strong> medical equipment,<br />

distribution <strong>and</strong> storage of drugs, regulatory systems,<br />

<strong>and</strong> budgeting <strong>and</strong> pricing<br />

505, 555 Business<br />

Because of the complexity of health care systems <strong>and</strong><br />

services, <strong>and</strong> the significant amount of money involved,<br />

the risk of corruption is high, that can result in the<br />

inequality of access to <strong>and</strong> quality of treatments.<br />

Sustainability Topics for Sectors: What do stakeholders want to know?<br />

HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />

May 2013<br />

Page 19 of 26


Sustainability<br />

Category<br />

Other<br />

Topic<br />

Corporate<br />

governance<br />

Topic<br />

Specification<br />

(if available)<br />

<strong>Healthcare</strong><br />

systems <strong>and</strong><br />

services<br />

Gender<br />

participation on<br />

governance<br />

bodies<br />

Explanation Reference(s) 1 Constituency<br />

Corruption in hospitals, informal payments for health<br />

care, in pharmaceutical sector <strong>and</strong> HIV/AIDS<br />

Fighting corruption in the health sector is a complex<br />

challenge. At one end of the scale are doctors <strong>and</strong> nurses<br />

who charge small informal payments to patients to<br />

supplement inadequate incomes. At the other end, <strong>and</strong><br />

far more pernicious, are the corrupt suppliers who offer<br />

bribes, <strong>and</strong> the health ministers <strong>and</strong> hospital<br />

administrators who accept bribes, or siphon millions of<br />

dollars from health budgets, skewing health policy <strong>and</strong><br />

depleting funds that should be spent building hospitals,<br />

buying medicines or employing staff.<br />

GOVERNANCE / EUROPE: boardroom lady boom: is it<br />

possible without quotas?<br />

On 22 June, the CapitalCom agency published its 2011<br />

survey into the boardroom gender mix of CAC 40<br />

companies, with fairly encouraging results: the<br />

proportion of women on the board has doubled in recent<br />

years, from 10.5% in 2009 to 20.8% in 2011.<br />

34, 506 Civil Society<br />

Organization<br />

389 Financial<br />

Markets &<br />

Information<br />

Users<br />

In January, the French parliament adopted legislation<br />

imposing quotas for the proportion of women on the<br />

board of major companies. Under the measures, the<br />

development of female board membership is m<strong>and</strong>atory<br />

<strong>and</strong> gradual: 20% for listed groups, public companies of<br />

an administrative, industrial <strong>and</strong> commercial nature by<br />

January 2014, rising to 40% by January 2017. The law<br />

also stipulates that companies with no women present<br />

on their board must appoint at least one within six<br />

Sustainability Topics for Sectors: What do stakeholders want to know?<br />

HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />

May 2013<br />

Page 20 of 26


Sustainability<br />

Category<br />

Topic<br />

Topic<br />

Specification<br />

(if available)<br />

Explanation Reference(s) 1 Constituency<br />

months of it being on the statute books (voted on 13<br />

January 2011). In France, some 2,000 companies are<br />

affected (the 650 largest listed firms <strong>and</strong> companies with<br />

more than 500 employees <strong>and</strong> those generating sales in<br />

excess of €50bn). In terms of sanctions for<br />

noncompliance, appointments that run counter to the<br />

parity principles are to be declared null <strong>and</strong> void <strong>and</strong><br />

attendance fees are to be temporarily suspended.<br />

At the European level <strong>and</strong> at the instigation of the Vicepresident<br />

of the European Commission, Viviane Reding,<br />

the European parliament will decide in March 2012 on<br />

whether to adopt common legislation on this matter (a<br />

m<strong>and</strong>atory proportion of women in decision-making<br />

positions of 30% in 2015 <strong>and</strong> 40% in 2020). This will<br />

depend on the level of improvement seen based on the<br />

selfregulation of European companies, in accordance<br />

with the equality initiative adopted by the European<br />

Commission in December 2010 <strong>and</strong> the European<br />

parliament resolution of 17 January 2008 calling for the<br />

Commission <strong>and</strong> member states to promote a balance<br />

between women <strong>and</strong> men on company boards,<br />

particularly where member states are shareholders.<br />

Europe as a whole illustrates the degree of hesitation<br />

between a soft-law approach <strong>and</strong> conventional<br />

legislation (quotas in this instance), but it is clear from<br />

the experience at national level that the second method<br />

tends to get much better results.<br />

Sustainability Topics for Sectors: What do stakeholders want to know?<br />

HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />

May 2013<br />

Page 21 of 26


Sustainability<br />

Category<br />

Topic<br />

Political<br />

accountability<br />

Topic<br />

Specification<br />

(if available)<br />

Explanation Reference(s) 1 Constituency<br />

There are various measures of political accountability<br />

that can be measured (contributions, disclosure, board<br />

oversight).<br />

Note that this topic is applicable to more than the three<br />

industries noted. Essentially the political accountability<br />

practices of any company that is owned by public<br />

stockholders. Political contributions, the amount of<br />

disclosure <strong>and</strong> board oversight are among the data items<br />

that would be helpful in a sustainability report.<br />

394, 616 Financial<br />

Markets &<br />

Information<br />

Users<br />

In making investment decisions (especially for investors<br />

interested in socially responsible investing) is would be<br />

helpful to underst<strong>and</strong> how a given company is exposed<br />

to political risk (i.e. are they backing the winning<br />

c<strong>and</strong>idate, are they subject to potential retribution, why<br />

do they find it necessary to make political contributions,<br />

etc.).<br />

I have found the information I reference to be helpful in<br />

constructing investment portfolios that take into account<br />

this attribute of sustainability. Since it is not currently an<br />

established parameter in the socially responsible<br />

investment industry (www.ussif.org), adoption by the<br />

Global Reporting Initiative would go a long way in<br />

moving the topic of political accountability forward.<br />

Sustainability Topics for Sectors: What do stakeholders want to know?<br />

HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />

May 2013<br />

Page 22 of 26


Sustainability<br />

Category<br />

Topic<br />

Public health<br />

service<br />

effectiveness<br />

Topic<br />

Specification<br />

(if available)<br />

Laboratory<br />

readiness -<br />

Outbreaks of<br />

novel, emerging<br />

<strong>and</strong> dangerous<br />

pathogens<br />

Explanation Reference(s) 1 Constituency<br />

Laboratories readiness <strong>and</strong> response for rapid detection<br />

<strong>and</strong> containment of outbreaks of emerging <strong>and</strong><br />

dangerous pathogens<br />

Outbreaks of emerging <strong>and</strong> dangerous pathogens are a<br />

great risk for public health<br />

591 Mediating<br />

Institution<br />

1<br />

All references can be found at https://www.globalreporting.org/reporting/sector-guidance/Topics-Research/Pages/default.aspx<br />

Sustainability Topics for Sectors: What do stakeholders want to know?<br />

HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />

May 2013<br />

Page 23 of 26


References<br />

All references can be found at https://www.globalreporting.org/reporting/sector-guidance/Topics-Research/Pages/default.aspx<br />

34<br />

Baghdadi-Sabeti, G. & Serhan, F., 2010. WHO Good Governance for Medicines Programme: An Innovative Approach to Prevent Corruption in the<br />

Pharmaceutical Sector, Geneva: World Health Organization (WHO).<br />

44 Becker, J., 2010. Minding the Gap: Research Priorities to Address Pharmaceuticals in the Environment, Arlington: Health Care Without Harm.<br />

66<br />

Castan Centre for Human Rights Law; International Business Leaders Forum; Office of the United Nations High Commissioner for Human Rights,<br />

2008. Human Rights Translated, A Business Reference Guide, New York: United Nations Global Compact.<br />

102 Davis, S. C., 2002. 10 Ways to reduce regulated medical wastes (RMW), Arlington: <strong>Healthcare</strong> without Harm.<br />

123<br />

232<br />

240<br />

Emmanuel, J. & Stringer, R., 2007. For Proper Disposal: A global inventory of alternative medical waste treatment technologies, Arlington:<br />

Health Care without harm.<br />

Greiner, T., Rossi, M., Thorpe, B. & Kerr, B., 2006. Healthy Business Strategies for Transforming the Toxic Chemical Economy, Spring Brook:<br />

Clean Production Action.<br />

Health Care Without Harm Europe, 2007. Preventing damage to the environment from pharmaceuticals: a primer, Prague: Health Care Without<br />

Harm Europe.<br />

241 Health Care Without Harm, 2001. Non-Incineration Medical Waste Treatment Facilities, Washington, D.C.: Health Care Without Harm.<br />

242<br />

Health Care Without Harm, 2001. Waste Minimization, Segregation <strong>and</strong> Recycling in Hospitals. [Online]<br />

Available at: http://www.noharm.org/lib/downloads/waste/Waste_Min_Seg_Recyc_in_Hosp.pdf,<br />

[Accessed 19 March 2013].<br />

2<strong>45</strong> Heineman, B. J., 2011. We May Never Know Leaders' Responsibility in Gulf Disaster, Boston: Harvard Business Review.<br />

253 Institute for Human Rights <strong>and</strong> Business (IHRB), 'The Dhaka Principles for Migration with Dignity', Dhaka, 2011.<br />

Sustainability Topics for Sectors: What do stakeholders want to know?<br />

HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />

May 2013<br />

Page 24 of 26


353<br />

Kershaw, P., Katsuhiko, S., Lee, S., Samseth, J., Woodring, D., & Smith, J., 2011. Plastic Debris in the Ocean. In United Nations Environment<br />

Programme (UNEP), UNEP Year Book 2011 (pp. 20-33). Nairobi: United Nations Early Warning <strong>and</strong> Assessment.<br />

357 Kulick, M., Nathanson, A. & Sirois, E., 2011. Menu of Change: Healthy food in health care, Arlington: Health Care Without Harm.<br />

362<br />

Aiken, L.H., Clarke, S.P., Sloane, D.M., Sochalski, J., Silber, J.H., 20025. Hospital Nurse Staffing <strong>and</strong> Patient Mortality, Nurse Burnout, <strong>and</strong> Job<br />

Dissatisfaction. Journal of the American Medical Association, 288(16), pp. 1987-1993.<br />

367 MacKerron, C., 2011. Unfinished Business: The Case for Extended Producer Responsibility for Post-Consumer Packaging, Oakl<strong>and</strong>: As You Sow.<br />

389° Natixis, 2011. Strategy Note Equity Research - Strategy/SRI: Monthly review June 2011, Paris: Natixis.<br />

394 Nowak, T., 2012. Low Fee Socially Responsible Investing. 1st ed. Grayslake: Quantum Financial Planning LLC.<br />

4<strong>45</strong><br />

489<br />

494<br />

496<br />

Prüss, A., Giroult, E. & Rushbrook, P., 1999. Safe Management of Wastes from Health-care Activities, Geneva: World Health Organization<br />

(WHO).<br />

Sutherl<strong>and</strong>, L., Easthope, T., Sattler, B., Welker-Hood, K., Wilburn, S., 2008. Guide to Choosing Safer Products <strong>and</strong> Chemicals, Arlington: Health<br />

Care Without Harm.<br />

The American Hospital Association (AHA), 2012. Eliminating Racial <strong>and</strong> Ethnic Disparities. [Online]<br />

Available at: http://www.aha.org/advocacy-issues/disparities/index.shtml<br />

[Accessed 29 March 2013].<br />

The Centers for Occupational <strong>and</strong> Environmental Health, University of California, 2008. Green Chemistry: Cornerstone to a Sustainable<br />

California, San Francisco: The Centers for Occupational <strong>and</strong> Environmental Health, University of California.<br />

505 Transparency International, 2006. Global Corruption Report 2006, London: Transparency International.<br />

506 Transparency International, 2006. Global Corruption Report 2006: Corruption <strong>and</strong> Health, London: Pluto Press.<br />

527<br />

United Nations Environment Programme (UNEP), 2012. Compendium of Technologies for Treatment/Destruction of <strong>Healthcare</strong> Waste, Nairobi:<br />

United Nations Environment Programme (UNEP).<br />

555 Vian, T. & Nordberg, C., 2008. Corruption in the Health Sector, Bergen: U4 - Chr. Michelsen Institute.<br />

Sustainability Topics for Sectors: What do stakeholders want to know?<br />

HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />

May 2013<br />

Page 25 of 26


583 World Health Organization (WHO), 2002. Prevention of Hospital-acquired Infections, Geneva: World Health Organization (WHO).<br />

584 World Health Organization (WHO), 2003. WHO Guide to cost-effectiveness analysis, Geneva: World Health Organization (WHO).<br />

586<br />

590<br />

World Health Organization (WHO), 2007. Infection Prevention <strong>and</strong> Control of Epidemic- <strong>and</strong> P<strong>and</strong>emic-prone Acute Respiratory Diseases in<br />

Health Care, Geneva: World Health Organization (WHO).<br />

World Health Organization (WHO), 2012. Pursuit of Responsible Use of Medicines: Sharing <strong>and</strong> Learning from Country Experiences, Geneva:<br />

World Health Organization (WHO).<br />

591 World Health Organization (WHO), 2012. Rapid Risk Assessment of Acute Public Health Events, Geneva: World Health Organization (WHO).<br />

593<br />

616<br />

World Health Organization (WHO), Department for Public Health <strong>and</strong> Environment Assessing <strong>and</strong> Managing Environmental Risks to Health,<br />

'WHO Core Principles for Achieving Safe <strong>and</strong> Sustainable Management of Health-care Waste', 2007.<br />

Zicklin Center for Business Ethics at the Wharton School of the University of Pennsylvania, 2012. CPA-Zicklin Index of Corporate Political<br />

Accountability <strong>and</strong> Disclosure, Washington, D.C.: Center for Political Accountability.<br />

° Resource available on request <strong>and</strong>/or for a fee.<br />

Sustainability Topics for Sectors: What do stakeholders want to know?<br />

HEALTHCARE PROVIDERS AND SERVICES, AND HEALTHCARE TECHNOLOGY<br />

May 2013<br />

Page 26 of 26

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!